Parsons Capital Management Inc. RI grew its holdings in shares of NeurAxis, Inc. (NASDAQ:NRXS – Free Report) by 797.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 116,726 shares of the company’s stock after acquiring an additional 103,726 shares during the quarter. Parsons Capital Management Inc. RI owned 1.67% of NeurAxis worth $274,000 at the end of the most recent quarter.
NeurAxis Trading Down 4.2 %
Shares of NeurAxis stock opened at $3.00 on Wednesday. The firm’s 50 day moving average is $2.70 and its 200 day moving average is $2.89. The firm has a market capitalization of $20.94 million, a PE ratio of -1.63 and a beta of 4.20. NeurAxis, Inc. has a 1 year low of $2.02 and a 1 year high of $3.89.
NeurAxis (NASDAQ:NRXS – Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.25) earnings per share for the quarter. The business had revenue of $0.67 million for the quarter.
About NeurAxis
NeurAxis, Inc, a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome.
Recommended Stories
- Five stocks we like better than NeurAxis
- Using the MarketBeat Dividend Tax Calculator
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- What Does the Future Hold for Eli Lilly?
- When to Sell a Stock for Profit or Loss
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Want to see what other hedge funds are holding NRXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeurAxis, Inc. (NASDAQ:NRXS – Free Report).
Receive News & Ratings for NeurAxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeurAxis and related companies with MarketBeat.com's FREE daily email newsletter.